JP2022543771A5 - - Google Patents
Info
- Publication number
- JP2022543771A5 JP2022543771A5 JP2022506328A JP2022506328A JP2022543771A5 JP 2022543771 A5 JP2022543771 A5 JP 2022543771A5 JP 2022506328 A JP2022506328 A JP 2022506328A JP 2022506328 A JP2022506328 A JP 2022506328A JP 2022543771 A5 JP2022543771 A5 JP 2022543771A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- chain variable
- variable domain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020903A JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880449P | 2019-07-30 | 2019-07-30 | |
| US62/880,449 | 2019-07-30 | ||
| PCT/US2020/044263 WO2021022039A1 (en) | 2019-07-30 | 2020-07-30 | Antigen-binding protein constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020903A Division JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543771A JP2022543771A (ja) | 2022-10-14 |
| JP2022543771A5 true JP2022543771A5 (https=) | 2023-06-28 |
| JP7635201B2 JP7635201B2 (ja) | 2025-02-25 |
Family
ID=72088381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506328A Active JP7635201B2 (ja) | 2019-07-30 | 2020-07-30 | 抗原結合タンパク質構築物及びその使用 |
| JP2025020903A Pending JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020903A Pending JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220281984A1 (https=) |
| EP (1) | EP4003534A1 (https=) |
| JP (2) | JP7635201B2 (https=) |
| KR (1) | KR20220053577A (https=) |
| CN (2) | CN120285218A (https=) |
| AU (1) | AU2020321368A1 (https=) |
| BR (1) | BR112022001693A2 (https=) |
| CA (1) | CA3149199A1 (https=) |
| IL (1) | IL290233A (https=) |
| MX (2) | MX2022001286A (https=) |
| WO (1) | WO2021022039A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66266B1 (sr) | 2021-02-03 | 2024-12-31 | Mythic Therapeutics Inc | Anti-met antitela i njihova primena |
| EP4526345A1 (en) | 2022-05-19 | 2025-03-26 | Mythic Therapeutics, Inc. | Ptk7-binding proteins with ph-dependent binding and uses thereof |
| CN115329965B (zh) * | 2022-08-16 | 2025-08-01 | 北京有竹居网络技术有限公司 | 数据处理方法和电子设备 |
| WO2024081729A2 (en) | 2022-10-12 | 2024-04-18 | Mythic Therapeutics, Inc. | Lrrc-15-binding protein constructs and uses thereof |
| US20240197906A1 (en) | 2022-12-11 | 2024-06-20 | Mythic Therapeutics, Inc. | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF |
| KR20260007365A (ko) | 2023-03-29 | 2026-01-13 | 마이틱 테라퓨틱스, 인크. | Trop2-결합 단백질 및 이의 용도 |
| EP4731670A2 (en) | 2023-06-23 | 2026-04-29 | Mythic Therapeutics, Inc. | Ph sensitive anti-itgb6 antibodies and uses thereof |
| TW202602935A (zh) | 2024-04-01 | 2026-01-16 | 美商米西克治療公司 | 抗原結合蛋白構築體及其用途 |
| WO2025245128A1 (en) | 2024-05-20 | 2025-11-27 | Mythic Therapeutics, Inc. | Antibody drug conjugates and therapeutic uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| JP5932670B2 (ja) * | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| CN102174106B (zh) * | 2011-03-17 | 2013-04-10 | 朱进 | 抗Met人源Fab及其阿霉素偶联物和其制法及应用 |
| EP2825553B1 (en) * | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| UA120981C2 (uk) * | 2015-09-18 | 2020-03-10 | Чугаі Сейяку Кабусікі Кайся | Антитіло, що зв'язується з il-8, та його застосування |
| SI3626273T1 (sl) * | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| KR102376582B1 (ko) * | 2016-06-17 | 2022-03-18 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
| MX420249B (es) * | 2016-09-29 | 2025-02-10 | Mitsubishi Tanabe Pharma Corp | Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos. |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| RS66266B1 (sr) * | 2021-02-03 | 2024-12-31 | Mythic Therapeutics Inc | Anti-met antitela i njihova primena |
-
2020
- 2020-07-30 MX MX2022001286A patent/MX2022001286A/es unknown
- 2020-07-30 CA CA3149199A patent/CA3149199A1/en active Pending
- 2020-07-30 US US17/630,824 patent/US20220281984A1/en active Pending
- 2020-07-30 KR KR1020227006745A patent/KR20220053577A/ko active Pending
- 2020-07-30 JP JP2022506328A patent/JP7635201B2/ja active Active
- 2020-07-30 AU AU2020321368A patent/AU2020321368A1/en active Pending
- 2020-07-30 EP EP20757450.0A patent/EP4003534A1/en active Pending
- 2020-07-30 BR BR112022001693A patent/BR112022001693A2/pt unknown
- 2020-07-30 CN CN202510154248.1A patent/CN120285218A/zh active Pending
- 2020-07-30 CN CN202080066488.1A patent/CN114746123A/zh active Pending
- 2020-07-30 WO PCT/US2020/044263 patent/WO2021022039A1/en not_active Ceased
-
2022
- 2022-01-28 MX MX2025011030A patent/MX2025011030A/es unknown
- 2022-01-30 IL IL290233A patent/IL290233A/en unknown
-
2025
- 2025-02-12 JP JP2025020903A patent/JP2025072609A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543771A5 (https=) | ||
| JP7607498B2 (ja) | 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| Arezumand et al. | Nanobodies as novel agents for targeting angiogenesis in solid cancers | |
| JP6670275B2 (ja) | 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体 | |
| Bell et al. | Differential tumor-targeting abilities of three single-domain antibody formats | |
| JP6817492B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| CN106573983B (zh) | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 | |
| JP6917357B2 (ja) | 癌治療に使用する放射標識抗体断片 | |
| JP2022535452A5 (https=) | ||
| Zhao et al. | Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model | |
| JP2022514786A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| JP2021506817A5 (https=) | ||
| CN111848805B (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
| JP2025510642A5 (https=) | ||
| JP2022534808A5 (https=) | ||
| JP2025181917A5 (https=) | ||
| JP2021516670A (ja) | 抗ｔｒａｉｌｒ２抗体−毒素−複合体およびその抗腫瘍治療における薬物用途 | |
| JP2022551844A5 (https=) | ||
| WO2023222135A9 (en) | A method of treating solid tumor | |
| JP2022514477A5 (https=) | ||
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP2024535851A5 (https=) | ||
| US20250197501A1 (en) | Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| HK40120258A (zh) | 治疗实体瘤的方法 |